Valuation: Galapagos NV

Market Cap 1.77B 0 2.03B 1.63B 1.52B 2.88B 193B 2.92B 19.56B 7.6B 94.79B 7.61B 7.44B 327B P/E 2026 *
-9.25x
P/E 2027 * -10.7x
Enterprise Value -882M -0 -1.01B -810M -755M -1.43B -96.03B -1.45B -9.73B -3.78B -47.16B -3.79B -3.7B -163B EV / Sales 2026 *
-5.86x
EV / Sales 2027 * -5.09x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-12
Director of Finance/CFO 43 2025-07-06
Chief Tech/Sci/R&D Officer 61 2026-06-07
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-12
Change 5-day change 1-year change 3-year change Capi.($)
+1.70%+6.89%+2.76%+7.65% 49.15B
+0.92%+6.21%+408.85%+607.44% 40.23B
+1.89%+11.06%+25.75%-7.89% 34.55B
+2.38%+8.10%+21.83%+66.94% 33.09B
+3.96%+6.07%+14.14%+37.68% 25.19B
+2.51%+4.94% - - 17.05B
+2.58%+7.24%+71.03%+132.17% 15.92B
+0.32%+1.58%+14.34%+19.26% 13.83B
-1.14%+7.52%+14.75%-30.83% 13.26B
Average +1.68%+5.99%+71.68%+104.05% 26.92B
Weighted average by Cap. +1.81%+6.31%+89.14%+131.73%

Financials

2026 *2027 *
Net sales 150M 0 172M 138M 129M 244M 16.39B 248M 1.66B 645M 8.05B 646M 632M 27.77B 132M 0 151M 121M 113M 214M 14.39B 218M 1.46B 566M 7.06B 567M 555M 24.38B
Net income -261M -0 -298M -239M -223M -423M -28.4B -430M -2.88B -1.12B -13.94B -1.12B -1.09B -48.12B -145M -0 -166M -133M -124M -236M -15.81B -239M -1.6B -622M -7.76B -623M -610M -26.79B
Net Debt -2.65B -0 -3.04B -2.44B -2.27B -4.31B -289B -4.37B -29.29B -11.38B -142B -11.4B -11.15B -490B -2.44B -0 -2.8B -2.25B -2.09B -3.97B -266B -4.03B -26.97B -10.48B -131B -10.5B -10.27B -451B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
B